Royalty Financing for Life Sciences
12:00 PM – 12:30 PM | Registration & Welcome
12:30 PM – 12:50 PM | What is Royalty Financing? Sebastian Gensior, Founder, Capital for Cures
A primer on royalty-based capital: how pharmaceutical royalty deals work and why institutional investors are allocating billions to this asset class.
12:50 PM – 1:10 PM | The Biotech Funding Crunch Michał Czarnuch, Partner & Co-Head Life Sciences, Rymarz Zdort Maruta
The IPO market is closed. Venture capital has retreated. Why revenue-based structures are moving from niche to necessity.
1:10 PM – 1:30 PM | Panel: Royalty Deals from the Operator's Perspective Moderator: Sebastian Gensior Bodo Marr, former Head of M&A / Treasury, MorphoSys (TBC) Michał Czarnuch, Rymarz Zdort Maruta
What makes an asset "royalty-financeable"? Key terms and lessons from the dealmaker's side.
1:30 PM – 3:30 PM | Networking